3,4-diaminopyridine treatment for Lambert-Eaton myasthenic syndrome in adults: a meta-analysis of randomized controlled trials
Abstract Background Lambert-Eaton myasthenic syndrome (LEMS) is a rare autoimmune disorder of neuromuscular transmission. The objective was to examine the efficacy and safety of 3,4-diaminopyridine (3,4-DAP) in patients with LEMS. Methods We searched several databases to identify relevant studies, i...
Salvato in:
| Autori principali: | , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMC
2021-09-01
|
| Serie: | BMC Neurology |
| Soggetti: | |
| Accesso online: | https://doi.org/10.1186/s12883-021-02405-3 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|